Modeling Alzheimer's risk using human TREM2-knockout microglia

Amanda McQuade from Dr. Mathew Blurton-Jones’s lab discusses her protocol for differentiating microglia from induced pluripotent stem cells (iPSCs) and the use of these microglia in vivo and in vitro to uncover the mechanisms of immune activation and neurodegeneration in Alzheimer’s disease. Based on the 2020 Nature Communications paper "Gene Expression and Functional Deficits Underlie TREM2-Knockout Microglia Responses in Human Models of Alzheimer’s Disease"

Publish Date: February 11, 2021 Views: 0

Request Webinar Form

Explore Our Products

STEMdiff™ Microglia Differentiation Kit

Differentiation kit for the generation of microglia precursors from human ES and iPS cell-derived hematopoietic progenitor cells
CloneR™

Defined supplement for single-cell cloning of human ES and iPS cells
STEMdiff™ Microglia Maturation Kit

Maturation kit for the generation of microglia from human ES and iPS cell-derived microglia precursors
STEMdiff™ Hematopoietic Kit

For differentiation of human ES or iPS cells into hematopoietic progenitor cells

Contact STEMCELL Technologies

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.

Modeling Alzheimer's risk using human TREM2-knockout microglia

Webinar: Modeling Alzheimer's risk using human TREM2-knockout microglia

Related Multimedia

How to Count hPSC Aggregates to Determine Plating Density for Maintenance and Differentiation

STEMCELL Journal Club: Patient-Derived Alzheimer’s Disease Modeling

Engineering the Hematopoietic System to Treat Non-Hematological Disorders

Item added to your cart

Explore Our Products

Contact STEMCELL Technologies